Zacks: Brokerages Anticipate Minerva Neurosciences (NERV) Will Announce Earnings of -$0.30 Per Share

Brokerages predict that Minerva Neurosciences (NASDAQ:NERV) will report earnings of ($0.30) per share for the current quarter, Zacks reports. Zero analysts have made estimates for Minerva Neurosciences’ earnings. Minerva Neurosciences also reported earnings per share of ($0.30) during the same quarter last year. The company is expected to issue its next earnings report on Thursday, May 3rd.

On average, analysts expect that Minerva Neurosciences will report full-year earnings of ($1.46) per share for the current financial year. For the next fiscal year, analysts forecast that the firm will report earnings of ($1.50) per share. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that that provide coverage for Minerva Neurosciences.

How to Become a New Pot Stock Millionaire

Minerva Neurosciences (NASDAQ:NERV) last released its quarterly earnings results on Monday, March 12th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.43) by $0.19.

NERV has been the subject of several recent analyst reports. Zacks Investment Research raised shares of Minerva Neurosciences from a “hold” rating to a “buy” rating and set a $7.25 price objective for the company in a report on Friday, March 16th. BidaskClub raised shares of Minerva Neurosciences from a “sell” rating to a “hold” rating in a report on Tuesday, January 16th. Finally, ValuEngine lowered shares of Minerva Neurosciences from a “sell” rating to a “strong sell” rating in a report on Sunday, December 31st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. Minerva Neurosciences currently has a consensus rating of “Hold” and a consensus target price of $12.75.

Hedge funds have recently made changes to their positions in the business. The Manufacturers Life Insurance Company grew its holdings in Minerva Neurosciences by 38.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,359 shares of the biopharmaceutical company’s stock worth $198,000 after acquiring an additional 6,251 shares in the last quarter. Trexquant Investment LP acquired a new position in shares of Minerva Neurosciences in the 3rd quarter valued at about $189,000. Goldman Sachs Group Inc. boosted its holdings in shares of Minerva Neurosciences by 47.8% in the 4th quarter. Goldman Sachs Group Inc. now owns 40,835 shares of the biopharmaceutical company’s stock valued at $247,000 after buying an additional 13,199 shares during the period. California State Teachers Retirement System boosted its holdings in shares of Minerva Neurosciences by 7.5% in the 2nd quarter. California State Teachers Retirement System now owns 44,537 shares of the biopharmaceutical company’s stock valued at $394,000 after buying an additional 3,100 shares during the period. Finally, Sterling Capital Management LLC boosted its holdings in shares of Minerva Neurosciences by 25.2% in the 3rd quarter. Sterling Capital Management LLC now owns 52,135 shares of the biopharmaceutical company’s stock valued at $396,000 after buying an additional 10,479 shares during the period. 70.13% of the stock is owned by institutional investors.

NERV traded down $0.10 during trading hours on Wednesday, reaching $6.15. 89,183 shares of the stock traded hands, compared to its average volume of 189,443. The firm has a market cap of $242.18, a price-to-earnings ratio of -5.65 and a beta of 1.42. Minerva Neurosciences has a fifty-two week low of $4.80 and a fifty-two week high of $11.15.

TRADEMARK VIOLATION NOTICE: This report was originally reported by WKRB News and is owned by of WKRB News. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://www.wkrb13.com/2018/04/02/zacks-brokerages-anticipate-minerva-neurosciences-nerv-will-announce-earnings-of-0-30-per-share.html.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia.

Get a free copy of the Zacks research report on Minerva Neurosciences (NERV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Minerva Neurosciences (NASDAQ:NERV)

Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply